Strategic Shift and Operational Execution
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
The company is undergoing a strategic transition from a leasing-heavy model to Direct Patient Care Services, which now serves as the primary engine for revenue growth.
Revenue growth of 15.9% was driven by increased treatment volumes at the Orlando PBRT facility, Rhode Island centers, and international Gamma Knife locations.
Management attributes improved performance in Rhode Island to stabilized physician staffing and enhanced clinical operations, which have led to more consistent patient throughput.
International growth is being spearheaded by the Puebla center, which is benefiting from improved reimbursement dynamics and ongoing operational ramp-up.
The leadership transition to Craig Tagawa as Interim CEO is intended to ensure continuity and leverage his 35 years of operational and financial experience with the firm.
Margin expansion is being driven by higher utilization across the network, though it is partially offset by the higher fixed-cost structure inherent in the Direct Patient Services model.
Expansion Pipeline and Financial Outlook
The Guadalajara Center in Mexico is expected to begin operations late in 2026, serving as a key pillar of the broader international expansion strategy.
Long-term growth in Rhode Island is supported by certificate of need approvals for a new radiation therapy center in Bristol and a proton beam center in Johnston.
Management expects the Bristol facility to open in approximately 18 to 24 months, while the Johnston proton beam facility is projected for a 24 to 30-month timeline.
The company anticipates improved year-over-year comparability in the leasing segment now that the impact of a major contract expiration from April 2025 has been lapped.
Financial performance is expected to improve as newer facilities continue to scale and move past the high-fixed-cost ramp-up phase.
Operational Risks and Structural Dynamics
Cost of revenue increased to $5.8 million due to higher staffing and maintenance costs as certain LINAC systems came out of warranty.
The company continues to report a net loss of $0.6 million, reflecting the heavy upfront investment required for the Direct Patient Services segment.
A Gamma Knife customer contract expiration in April 2025 created a headwind for the leasing segment that has only recently been fully offset by volume growth elsewhere.
The company is actively managing its capital structure and remains in discussions with its lender regarding debt extensions and compliance.
